First successful outcomes of pegvaliase (PALYNZIQ) in children
Abstract Background PKU is an autosomal recessive hereditary inborn error of metabolism caused by a lack of phenylalanine hydroxylase enzyme activity. Pegvaliase (PALYNZIQ®) treatment has been approved to reduce blood Phe concentrations in adult phenylketonuria patients with uncontrolled blood Phe c...
Saved in:
Main Authors: | Majid Alfadhel (Author), Rayyan Albarakati (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria
by: Tasmina Hydery, et al.
Published: (2019) -
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
by: Yulan Qi, et al.
Published: (2021) -
Enzyme replacement therapy for Fabry disease: some answers but more questions
by: Majid Alfadhel, et al.
Published: (2011) -
Spinal Cord Involvement in Pediatric-Onset Metabolic Disorders With Mendelian and Mitochondrial Inheritance
by: Brahim Tabarki, et al.
Published: (2021) -
Does Universal SEL Promote Academic Success? Examining Learner Outcomes Under Routine Conditions in First-Grade Classrooms
by: Susan Crandall Hart, et al.
Published: (2024)